Literature DB >> 10536244

Preparation and in vitro characterization of HSA-mPEG nanoparticles.

W Lin1, M C Garnett, E Schacht, S S Davis, L Illum.   

Abstract

Surface modified human serum albumin (HSA) nanoparticles with a size of approximately 150 nm in diameter were prepared from a PEG-HSA conjugate, methoxy-polyethylene glycol modified human serum albumin (HSA-mPEG) using a coacervation method and crosslinked with glutaraldehyde. The zeta-potential of the surface modified nanoparticles was significantly lower than that of unmodified HSA nanoparticles. The existence of a hydrated steric barrier surrounding the nanoparticles was confirmed by electrolyte and pH induced flocculation tests. The surface modified nanoparticles showed a reduced plasma protein adsorption on the particle surface compared with unmodified particles.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536244     DOI: 10.1016/s0378-5173(99)00253-7

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

Review 1.  Advances in the use of tocols as drug delivery vehicles.

Authors:  Panayiotis P Constantinides; Jihong Han; Stanley S Davis
Journal:  Pharm Res       Date:  2006-01-25       Impact factor: 4.200

2.  Suppression of agglomeration of ciprofloxacin-loaded human serum albumin nanoparticles.

Authors:  P Vijayaraj Kumar; Narendr K Jain
Journal:  AAPS PharmSciTech       Date:  2007-03-02       Impact factor: 3.246

Review 3.  Nanoparticulate systems for growth factor delivery.

Authors:  Sufeng Zhang; Hasan Uludağ
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

4.  Design and evaluation of an emulsion vehicle for paclitaxel. I. Physicochemical properties and plasma stability.

Authors:  Jihong Han; Stanley S Davis; Catherine Papandreou; Colin D Melia; Clive Washington
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

5.  Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.

Authors:  Birgit Spänkuch; Isabel Steinhauser; Heidrun Wartlick; Elisabeth Kurunci-Csacsko; Klaus I Strebhardt; Klaus Langer
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

6.  Delivery luteolin with folacin-modified nanoparticle for glioma therapy.

Authors:  Cong Wu; Qian Xu; Xinyue Chen; Jiagang Liu
Journal:  Int J Nanomedicine       Date:  2019-09-16

Review 7.  Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice.

Authors:  Sabrina Valetti; Simona Mura; Barbara Stella; Patrick Couvreur
Journal:  J Nanobiotechnology       Date:  2013-12-10       Impact factor: 10.435

8.  Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).

Authors:  Sonali Kumari; Saad M Ahsan; Jerald M Kumar; Anand K Kondapi; Nalam M Rao
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.